Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Lactobacillus, a genus of probiotic bacteria, has been investigated for its potential role in preventing and managing bladder infections, particularly recurrent urinary tract infections (rUTIs). The scientific rationale is based on the ability of certain Lactobacillus strains to colonize the vaginal and urinary tract mucosa, where they may inhibit the growth and adherence of pathogenic bacteria (such as Escherichia coli) through competitive exclusion, production of lactic acid, and other antimicrobial substances.

Clinical studies have shown mixed results. Some randomized controlled trials have suggested that intravaginal or oral administration of specific Lactobacillus strains (e.g., L. rhamnosus GR-1 and L. reuteri RC-14) may reduce the risk of recurrent UTIs in women compared to placebo, though the effect sizes are modest and not all studies have found significant results. Systematic reviews and meta-analyses generally conclude that while there is some evidence for benefit, it is limited by heterogeneity in study design, probiotic strains, and dosing regimens. The current scientific consensus is that Lactobacillus supplementation is a promising adjunctive strategy, particularly for women with frequent recurrences who wish to avoid antibiotics, but it is not yet established as a standard therapy.

Overall, while the scientific evidence is growing, it remains moderate in quality and strength, justifying a rating of 2 out of 5. More rigorous, large-scale trials are needed to determine efficacy, optimal strains, and dosing protocols.

More about Lactobacillus mixed)
More about Bladder Infection

Other ingredients used for Bladder Infection

Other health conditions supported by Lactobacillus mixed)

Products containing Lactobacillus mixed)